Targets › LASV
2 programs from 2 companies in 2 trials: 2 Phase 2; Infectious disease; next expected readout Jun 2027.
Open in Phaseline: the race on LASV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Irrua Specialist Teaching Hospital | Favipiravir RNA-directed RNA polymerase inhibitor | LASV | Phase 2 | Lassa Fever | Jun 2027 |
| International AIDS Vaccine Initiative | rVSV∆G-LASV-GPC Recombinant vesicular stomatitis virus (rVSV) expressing Lassa virus glycoprotein (GPC) | LASV | Phase 2 | Lassa Fever | Jun 2027 |
Lassa Fever (2)
small molecule (2)
International AIDS Vaccine Initiative (1) Irrua Specialist Teaching Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.